Market Research Logo

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Gastroesophageal (GE) Junction Carcinomas Overview
Therapeutics Development
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis
Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies
Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies
Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development
Amgen Inc.
Aslan Pharmaceuticals Pte. Ltd.
AstraZeneca Plc
Basilea Pharmaceutica AG
Bristol-Myers Squibb Company
Celltrion, Inc.
Exelixis, Inc.
GlaxoSmithKline Plc
Hetero Drugs Limited
Merck & Co., Inc.
Merck KGaA
NantKwest, Inc.
Ono Pharmaceutical Co., Ltd.
Sorrento Therapeutics, Inc.
Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afuresertib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAL-101553 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target HER2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DKN-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FS-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gefitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haNK Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipilimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nimotuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
varlitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products
Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones
Featured News & Press Releases
Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca Plc, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by GlaxoSmithKline Plc, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Hetero Drugs Limited, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by NantKwest, Inc., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H2 2015
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report